In stage 1 ( dose finding ) , 124 patients who responded to rituximab induction were randomly assigned to SC rituximab ( 375 mg/m2 , 625 mg/m2 , or an additional group at 800 mg/m2 ) or IV rituximab ( 375 mg/m2 ) .